Redeye comments on Mendus’ Q4 report. We have updated our valuation scenarios and present a new base case. We still view AML as the most valuable indication. However, in the long term, as more clinical data become available, CML could take the lead with multi-blockbuster potential. We discuss recent developments in the CML space.
LÄS MER
